Capricor Therapeutics (CAPR) Capital Expenditures (2011 - 2026)

Capricor Therapeutics' Capital Expenditures history runs 15 years deep, the most recent figure standing at $5.1 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 471.61% year-over-year to $5.1 million; the TTM figure through Mar 2026 stood at $7.1 million (up 390.28% YoY), while the FY2025 annual figure was $2.9 million, up 148.91% from the prior year.
• Capital Expenditures was $5.1 million for Q1 2026 at Capricor Therapeutics, up from $1.7 million in the prior quarter.
• In the past five years, Capital Expenditures ranged from a high of $5.1 million in Q1 2026 to a low of $9145.0 in Q3 2024.
• Historically, Capital Expenditures has averaged $735584.9 across 5 years, with a median of $488798.0 in 2024.
• The sharpest annual moves came in 2022 and 2024: Capital Expenditures jumped 1437.75% in 2022, then sank 96.61% in 2024.
• A 5-year view of Capital Expenditures shows it stood at $694044.0 in 2022, then slipped by 19.51% to $558604.0 in 2023, then slipped by 12.5% to $488798.0 in 2024, then soared by 240.61% to $1.7 million in 2025, then soared by 207.63% to $5.1 million in 2026.
• The last three Capital Expenditures figures came in at $5.1 million (Q1 2026), $1.7 million (Q4 2025), and $55843.0 (Q3 2025), per Business Quant data.